NICE issues positive Final Appraisal Determination recommending the use of Basilea's Toctino
The FAD published today will become the Institute's final guidance to the National Health Service (NHS) at the end of August, according to NICE's publication schedule, assuming no appeals are made by the appraisal consultees.
"The positive Final Appraisal Determination is an important milestone for Basilea and is confirmation of the value Toctino brings to patients and the healthcare community," said Dr. Anthony Man, Chief Executive Officer, Basilea Pharmaceutica Ltd. "The NICE recommendation should provide patients in England and Wales who suffer from severe chronic hand eczema a real chance to obtain hands cleared of eczema and the possibility to resume normal activities."
NICE determined that Toctino®, an innovative therapy shown to be highly effective in phase III trials, is a cost-effective use of NHS resources. Toctino® is recommended for patients with severe disease, which is defined by a physician's global assessment and a dermatology life quality index score of 15 or more.
In March of this year the Scottish Medicine's Consortium determined Toctino® should be made available to patients in Scotland.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.